Expanded Access Study for Renal Transplant Patients With Envarsus XR™: Envarsus 3007

Veloxis Pharmaceuticals0 个研究点开始时间: 2015年4月8日最近更新: 2016年1月20日

适应症

试验速览

阶段: 不适用
状态: Approved For Marketing
发起方

研究概览入排标准研究者记录与标识符相似试验

研究概览

简要总结

Open label, multi-center, expanded access study for renal transplant patients with once daily Envarsus XR (Tacrolimus).

详细描述

The study is designed to facilitate expanded access of Envarsus XR treatment to renal transplant patients. Patients are identified by the site investigator as a patient who has experienced favorable outcomes while in an Envarsus XR (LCP-Tacro) clinical study and/or the site investigator has identified a renal transplant patient with a medical need for an alternative tacrolimus treatment versus the patient's current tacrolimus treatment.

研究设计

研究类型: Expanded Access

入排标准

年龄范围: 18 Years 至 —（Adult, Older Adult）
性别: All
接受健康志愿者: 否

入选标准

•Eligible patients will fulfill all of the following criteria:
•Patient age ≥18years old
•Willing to give written informed consent and is able to speak, write and understand English
•Patient understands potential risks or benefits with treatment of Envarsus XR
•Patients who have received a primary or secondary kidney transplant
•Patient who have received prior treatment with Envarsus XR (LCP-Tacro) and who are not currently participating in an Envarsus/LCP-Tacro study OR
•The treating Investigator has identified the patient as having a medical necessity for switching from their current tacrolimus treatment to Envarsus XR: Investigator is aware the medical necessity for switching is not related to the inability to purchase available tacrolimus.

排除标准

•Patients fulfilling any of the following criteria are NOT eligible for study inclusion:
•Recipients of organ transplants other than kidney
•Pregnant or nursing (lactating) women, or planning to become pregnant, where pregnancy is defined as a state of female after conception and until the termination of gestation, confirmed by a positive hCG serum or urine laboratory test.
•Women of child-bearing potential, defined as all women physiologically capable of becoming pregnant who are unwilling to use a defined SOC method of contraception, UNLESS they are
•Women whose career, lifestyle, or sexual orientation preclude intercourse with a male partner
•Women whose partners have been sterilized by vasectomy or other medically approved means

研究者

发起方

Veloxis Pharmaceuticals

申办方类型

Industry

责任方

Sponsor

相似试验

已完成

4 期

Everolimus in Combination With Cyclosporine Microemulsion in de Novo Renal Transplant RecipientsKidney Transplantation

NCT00170885Novartis

已完成

4 期

Advagraf/Prograf Conversion TrialRenal TransplantKidney Pancreas Transplant

NCT01410162Norman Muirhead53

撤回

不适用

Observational Registry Study of Renal Transplant PatientsKidney Transplant

NCT01284257Novartis Pharmaceuticals

撤回

3 期

Study of the Effect of Everolimus Immunosuppressive Combination Therapies on Renal Function When Used as a Maintenance Treatment for Liver Transplant Patients.Liver Transplantation

NCT03596970Novartis Pharmaceuticals

已完成

4 期

Kidney Spare the Nephron (STN) Study - A Study of CellCept (Mycophenolate Mofetil) and Rapamune (Sirolimus) in Kidney Transplant RecipientsKidney Transplantation

NCT00121810Hoffmann-La Roche305